
Tsumura & Co
TSE:4540

Tsumura & Co
Accounts Payable
Tsumura & Co
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Tsumura & Co
TSE:4540
|
Accounts Payable
ÂĄ20.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
25%
|
CAGR 10-Years
22%
|
|
![]() |
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Accounts Payable
ÂĄ460.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
![]() |
Daiichi Sankyo Co Ltd
TSE:4568
|
Accounts Payable
ÂĄ564.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
![]() |
Otsuka Holdings Co Ltd
TSE:4578
|
Accounts Payable
ÂĄ220B
|
CAGR 3-Years
9%
|
CAGR 5-Years
21%
|
CAGR 10-Years
5%
|
|
![]() |
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Accounts Payable
ÂĄ79B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
![]() |
Astellas Pharma Inc
TSE:4503
|
Accounts Payable
ÂĄ204.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-1%
|
Tsumura & Co
Glance View
Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.

See Also
What is Tsumura & Co's Accounts Payable?
Accounts Payable
20.4B
JPY
Based on the financial report for Dec 31, 2024, Tsumura & Co's Accounts Payable amounts to 20.4B JPY.
What is Tsumura & Co's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
22%
Over the last year, the Accounts Payable growth was 50%. The average annual Accounts Payable growth rates for Tsumura & Co have been 21% over the past three years , 25% over the past five years , and 22% over the past ten years .